Published in Eur Urol on January 01, 2003
Correlation between serum prostate-specific antigen and cancer volume in prostate glands of different sizes. Urology (2010) 1.64
Prognostic factors in prostate cancer. Diagn Pathol (2006) 0.99
The independent value of tumour volume in a contemporary cohort of men treated with radical prostatectomy for clinically localized disease. BJU Int (2009) 0.91
The association between tumour density and prostate cancer recurrence following radical prostatectomy. Can Urol Assoc J (2011) 0.88
Impact of capsular incision on biochemical recurrence after radical perineal prostatectomy. Prostate Cancer Prostatic Dis (2009) 0.86
Calculated tumor volume is an independent predictor of biochemical recurrence in patients who underwent retropubic radical prostatectomy. Adv Urol (2012) 0.85
Maximum tumor diameter is not an independent prognostic factor in high-risk localized prostate cancer. World J Urol (2008) 0.83
Do racial differences in prostate size explain higher serum prostate-specific antigen concentrations among black men? Urology (2007) 0.81
Tumor volume as a predictor of adverse pathologic features and biochemical recurrence (BCR) in radical prostatectomy specimens: a tale of two methods. World J Urol (2010) 0.79
Factors determining biochemical recurrence in low-risk prostate cancer patients who underwent radical prostatectomy. Turk J Urol (2015) 0.75
Total intraglandular and index tumor volumes predict biochemical recurrence in prostate cancer. Virchows Arch (2016) 0.75
Maximum tumor diameter adjusted to the risk profile predicts biochemical recurrence after radical prostatectomy. Virchows Arch (2014) 0.75
Tumor volume improves the long-term prediction of biochemical recurrence-free survival after radical prostatectomy for localized prostate cancer with positive surgical margins. World J Urol (2016) 0.75
Methods for volume assessment of prostate cancer. Eur Radiol (2004) 0.75
Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol (2006) 5.10
Prostate cancer detection rate in patients with repeated extended 21-sample needle biopsy. Eur Urol (2008) 3.83
Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol (2005) 3.15
Safety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience. J Urol (2004) 3.06
Extended 21-sample needle biopsy protocol for diagnosis of prostate cancer in 1000 consecutive patients. Eur Urol (2007) 2.92
Extensive biopsies and transurethral prostate resection in men with previous negative biopsies and high or increasing prostate specific antigen. J Urol (2009) 2.77
Positive surgical margin appears to have negligible impact on survival of renal cell carcinomas treated by nephron-sparing surgery. Eur Urol (2009) 2.41
Evaluation of combined oncological and functional outcomes after radical prostatectomy: trifecta rate of achieving continence, potency and cancer control--a literature review. Urology (2010) 2.19
Ureteral and multifocal tumours have worse prognosis than renal pelvic tumours in urothelial carcinoma of the upper urinary tract treated by nephroureterectomy. Eur Urol (2011) 2.19
Impact of body mass index on perioperative morbidity, oncological, and functional outcomes after extraperitoneal laparoscopic radical prostatectomy. Urology (2012) 2.13
The European Association of Urology (EAU) guidelines methodology: a critical evaluation. Eur Urol (2008) 2.04
Renal cell carcinoma (RCC) in patients with end-stage renal disease exhibits many favourable clinical, pathologic, and outcome features compared with RCC in the general population. Eur Urol (2011) 1.87
Urinary collecting system invasion is an independent prognostic factor of organ confined renal cell carcinoma. J Urol (2009) 1.83
Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans. Hum Mol Genet (2005) 1.74
Gene expression signatures predict outcome in non-muscle-invasive bladder carcinoma: a multicenter validation study. Clin Cancer Res (2007) 1.68
Prognostic impact of tumor size on pT2 renal cell carcinoma: an international multicenter experience. J Urol (2007) 1.67
Oncologic outcome after extraperitoneal laparoscopic radical prostatectomy: midterm follow-up of 1115 procedures. Eur Urol (2009) 1.63
External validation of the updated partin tables in a cohort of French and Italian men. Int J Radiat Oncol Biol Phys (2008) 1.58
The role of biopsy core number in selecting prostate cancer patients for active surveillance. Eur Urol (2009) 1.54
Constitutive activation of the androgen receptor by a point mutation in the hinge region: a new mechanism for androgen-independent growth in prostate cancer. Int J Cancer (2004) 1.54
Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b. Carcinogenesis (2005) 1.54
Beta-catenin-related anomalies in apoptosis-resistant and hormone-refractory prostate cancer cells. Clin Cancer Res (2003) 1.52
Expression of estrogen related proteins in hormone refractory prostate cancer: association with tumor progression. J Urol (2010) 1.52
Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J Clin Oncol (2004) 1.52
Acute bacterial prostatitis after transrectal ultrasound-guided prostate biopsy: epidemiological, bacteria and treatment patterns from a 4-year prospective study. Int J Urol (2013) 1.51
Can we improve the definition of high-risk, hormone naïve, non-metastatic prostate cancer? BJU Int (2014) 1.44
Oncologic outcomes and survival in pT0 tumors after radical cystectomy in patients without neoadjuvant chemotherapy: results from a large multicentre collaborative study. Ann Surg Oncol (2011) 1.42
Radical cystectomy and orthotopic bladder replacement in females. Eur Urol (2006) 1.42
Efficacy and tolerance of one-third full dose bacillus Calmette-Guérin maintenance therapy every 3 months or 6 months: two-year results of URO-BCG-4 multicenter study. Int J Urol (2014) 1.42
International Prostate Symptom Score is a predictive factor of lower urinary tract symptoms after radical prostatectomy. Int J Urol (2015) 1.41
Sexual dysfunction is common and overlooked in female patients with hypertension. J Sex Marital Ther (2002) 1.40
Steerable antegrade stenting: a new trick of the trade. Int Braz J Urol (2007) 1.39
Prospective evaluation of a 21-sample needle biopsy procedure designed to improve the prostate cancer detection rate. Urology (2003) 1.28
Relationship between age at diagnosis and clinicopathologic features of renal cell carcinoma. Eur Urol (2006) 1.27
The management of acute urinary retention in France: a cross-sectional survey in 2618 men with benign prostatic hyperplasia. BJU Int (2006) 1.23
Clinicopathological features and prognosis of synchronous bilateral renal cell carcinoma: an international multicentre experience. BJU Int (2007) 1.19
Analysis of outcomes after radical prostatectomy in patients eligible for active surveillance (PRIAS). BJU Int (2012) 1.18
Radical retropubic versus laparoscopic prostatectomy: a prospective comparison of functional outcome. Urology (2003) 1.18
Prognostic value of EGF receptor and tumor cell proliferation in bladder cancer: therapeutic implications. Urol Oncol (2004) 1.15
Immunocyt test improves the diagnostic accuracy of urinary cytology: results of a French multicenter study. J Urol (2003) 1.12
Acute hypoxia increases the aggressive characteristics and survival properties of prostate cancer cells. Prostate (2003) 1.12
Closing the tract of mini-percutaneous nephrolithotomy with gelatine matrix hemostatic sealant can replace nephrostomy tube placement. Urology (2006) 1.10
Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients. BJU Int (2010) 1.10
[Emphysematous cystitis complicated by bladder perforation: diagnosis and treatment of a rare case]. Prog Urol (2004) 1.10
Positive surgical margins in laparoscopic radical prostatectomy: the impact of apical dissection, bladder neck remodeling and nerve preservation. J Urol (2003) 1.10
Morbidity and clinical outcome of nephron-sparing surgery in relation to tumour size and indication. Eur Urol (2007) 1.08
The relationship between Prostate CAncer gene 3 (PCA3) and prostate cancer significance. BJU Int (2011) 1.08
Mutations in TP53, but not FGFR3, in urothelial cell carcinoma of the bladder are influenced by smoking: contribution of exogenous versus endogenous carcinogens. Carcinogenesis (2004) 1.07
Prospective evaluation of an extended 21-core biopsy scheme as initial prostate cancer diagnostic strategy. Eur Urol (2012) 1.07
Urinary continence and erectile function: a prospective evaluation of functional results after radical laparoscopic prostatectomy. Eur Urol (2002) 1.06
Metachronous bilateral renal cell carcinoma: risk assessment, prognosis and relevance of the primary-free interval. J Urol (2007) 1.06
Saturation biopsy protocol enhances prediction of pT3 and surgical margin status on prostatectomy specimen. World J Urol (2006) 1.05
Clinical evaluation of the PCA3 assay in guiding initial biopsy decisions. J Urol (2011) 1.04
Analysis of complications from 600 retroperitoneoscopic procedures of the upper urinary tract during the last 10 years. World J Urol (2008) 1.04
Radical prostatectomy by the retropubic, perineal and laparoscopic approach: 12 years of experience in one center. Eur Urol (2002) 1.03
Impact of the primary Gleason pattern on biochemical recurrence-free survival after radical prostatectomy: a single-center cohort of 1,248 patients with Gleason 7 tumors. World J Urol (2010) 1.03
Combined reporting of cancer control and functional results of radical prostatectomy. Eur Urol (2003) 1.02